search
Back to results

Multi-Centre Gastroschisis Interventional Study Across Sub-Saharan Africa

Primary Purpose

Gastroschisis

Status
Unknown status
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Pre-hospital interventional care bundle
In-hospital interventional care bundle
Sponsored by
King's College London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastroschisis focused on measuring Gastroschisis, Sub-Saharan Africa, Low-resource settings, Low- and middle-income countries, Mortality, Outcomes, Implementation science, Intervention

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • all neonates presenting primarily to the study centre with simple gastroschisis regardless of weight, gestational age or co-morbidities.

Exclusion Criteria:

  • all neonates with 'complex gastroschisis' requiring surgical intervention for bowel necrosis, perforation, atresia or other reason.

Sites / Locations

  • McGill University
  • Korle-Bu Teaching HospitalRecruiting
  • Komfo Anokye Teaching Hospital
  • Tamale Teaching HospitalRecruiting
  • Kamuzu Central Hospital
  • Muhimbili National Hospital
  • King's Centre for Global Health and Health Partnerships, King's College London
  • University Teaching Hospital
  • Arthur Davison Children's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Active Comparator

Arm Label

Pre-intervention

Post-intervention

Arm Description

Patients presenting with simple gastroschisis during the pre-intervention phase will receive the current care provided by the study sites (no intervention).

Patients presenting with simple gastroschisis during the post-implementation phase will receive the interventional care bundle if consent for participation is provided.

Outcomes

Primary Outcome Measures

All-cause, in-hospital mortality
Percentage of patients with gastroschisis dying in hospital during their primary admission.

Secondary Outcome Measures

Percentage of patients experiencing a major complication within 30-days of primary intervention*
Major complications are secondary bowel ischaemia, necrosis or perforation requiring resection**, abdominal compartment syndrome*** or need for further unplanned surgical intervention. *Defined as the first bowel intervention the neonate received including silo application or primary closure. **Defined as bowel necrosis or perforation that was not present prior to primary intervention and hence occurred after primary intervention. ***Defined as respiratory insufficiency secondary to compromised tidal volumes, decreased urine output by falling renal perfusion (<1ml/kg/hr) and any other organ dysfunction caused by increased intra-abdominal pressure (based on clinical judgement - the pressure does not have to be measured to fulfil the criteria).
Length of hospital stay amongst survivors
In days.
Time to full enteral feeds
In days
Need for ventilation
Yes/ no. This does not include ventilation given during anaesthesia for intervention(s).
Duration of ventilation
IN days. All ventilation types included.

Full Information

First Posted
September 12, 2018
Last Updated
February 25, 2020
Sponsor
King's College London
Collaborators
Korle-Bu Teaching Hospital, Accra, Ghana, Komfo Anokye Teaching Hospital, Tamale Teaching Hospital, Tamale, Ghana, University Teaching Hospital, Lusaka, Zambia, Arthur Davison Children's Hospital, Kamuzu Central Hospital, Muhimbili National Hospital, Dar es Salaam, Tanzania.
search

1. Study Identification

Unique Protocol Identification Number
NCT03724214
Brief Title
Multi-Centre Gastroschisis Interventional Study Across Sub-Saharan Africa
Official Title
Developing and Implementing an Interventional Bundle to Reduce Mortality From Gastroschisis in Low-Resource Settings
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 8, 2018 (Actual)
Primary Completion Date
November 8, 2020 (Anticipated)
Study Completion Date
January 31, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
King's College London
Collaborators
Korle-Bu Teaching Hospital, Accra, Ghana, Komfo Anokye Teaching Hospital, Tamale Teaching Hospital, Tamale, Ghana, University Teaching Hospital, Lusaka, Zambia, Arthur Davison Children's Hospital, Kamuzu Central Hospital, Muhimbili National Hospital, Dar es Salaam, Tanzania.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is a multi-centre interventional study at seven tertiary paediatric surgery centres in Ghana, Zambia, Malawi and Tanzania aimed at reducing mortality from gastroschisis.
Detailed Description
Background: Gastroschisis has a great disparity in outcomes globally with less than 4% mortality in high-income countries (HICs) and over 90% mortality in many tertiary paediatric surgery centres across sub-Saharan Africa (SSA), including the study centres. Low-technology, cost-effective, evidence-based interventions are available with the potential for improved outcomes in low-resource settings. Aim: To develop, implement and prospectively evaluate an interventional care bundle to reduce mortality from gastroschisis in seven tertiary paediatric surgery centres across SSA. Study Design: A hybrid type 2 effectiveness-implementation study design will be utilised, which focusses equally on the effectiveness of the intervention through analysing clinical outcomes and effectiveness of the implementation through analysis of service delivery and implementation outcomes. Methods: Using current literature an evidence-based, low-technology interventional care bundle has been developed with both pre-hospital and in-hospital components. During 2018 a systematic review, qualitative study and Delphi process will provide further evidence in order to optimise the interventional bundle and implementation strategy for use in low-resource environments. The interventional care bundle has core components, which will remain consistent across the seven sites, and adaptable components, which will be determined through in-country co-development meetings with all relevant members of the multi-disciplinary team. Across the seven study sites it is estimated that 180-289 patients will be included in the study, which has the potential to determine a difference in pre- and post-intervention mortality between 10-15%. Implementation will take place over a 4-week period at each of the study sites between April - December 2019. Pre- and post-interventional data will be collected on clinical, service delivery and implementation outcomes between September 2018 to October 2020 (2-years of patient recruitment at each site with a 30-day post primary intervention follow-up period). The primary clinical outcome will be all-cause, in-hospital mortality. Secondary outcomes include the occurrence of a major complication, length of hospital stay and time to full enteral feeds. Service delivery outcomes include time to hospital and primary intervention and adherence to the pre-hospital and in-hospital management protocols. Implementation outcomes will include acceptability, adoption, appropriateness, feasibility, fidelity, coverage, cost and sustainability. Expected Results: Pre- and post-intervention clinical outcomes will be compared using Chi-squared analysis, unpaired t-test and/ or Mann-Whitney test. Time-series analysis will be undertaken using Statistical Process Control to identify significant trends and shifts in outcome overtime. Multivariate logistic regression analysis will be used to identify both clinical and implementation factors affecting outcome with adjustment for confounders. P<0.05 will be deemed significant. Outcome: This will be the first multi-centre interventional study to the investigator's knowledge aimed at reducing mortality from gastroschisis in low-resource settings. If successful, detailed evaluation of both the clinical and implementation components of the study will allow sustainability in the study sites and further scale-up.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroschisis
Keywords
Gastroschisis, Sub-Saharan Africa, Low-resource settings, Low- and middle-income countries, Mortality, Outcomes, Implementation science, Intervention

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Pre and post study design. All patients presenting with simple gastroschisis during the pre-intervention phase will receive the current care provided by the study site. All patients with simple gastroschisis presenting to a study site following implementation will receive the interventional care bundle (if consent is provided).
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
235 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Pre-intervention
Arm Type
No Intervention
Arm Description
Patients presenting with simple gastroschisis during the pre-intervention phase will receive the current care provided by the study sites (no intervention).
Arm Title
Post-intervention
Arm Type
Active Comparator
Arm Description
Patients presenting with simple gastroschisis during the post-implementation phase will receive the interventional care bundle if consent for participation is provided.
Intervention Type
Combination Product
Intervention Name(s)
Pre-hospital interventional care bundle
Intervention Description
The interventional care bundle will include pre-hospital and in-hospital components and core and adaptable components. All seven centres will implement the core pre-hospital and in-hospital components. Implementation of the adaptable components will be decided by the local team to optimise the interventional care bundle to the local environment. Pre-hospital core components: 1) covering the bowel in clear plastic, 2) administering intravenous fluids, 3) keeping the neonate warm, 4) transferring to a study centre as soon as possible. This will be implemented as a pre-hospital gastroschisis care protocol to district and secondary level hospitals who refer patients with gastroschisis to the study centres. Pre-hospital adaptable components: 1) the strategy for disseminating the pre-hospital gastroschisis care protocol.
Intervention Type
Combination Product
Intervention Name(s)
In-hospital interventional care bundle
Intervention Description
In-hospital core components: 1) use of a standardised care protocol, 2) neonatal resuscitation and ward care including intravenous access, intravenous fluids, maintenance of normothermia, appropriate antibiotics, regular monitoring and infection control, 3) gastroschisis reduction and sutureless closure using a preformed silo and avoidance of neonatal anaesthesia and surgery, 4) early establishment of breastfeeding and an enhanced enteral feeding programme. In-hospital adaptable components: 1) administration of parenteral nutrition for neonates who have survived for 1-week in hospital, 2) maternal involvement in monitoring and basic management, 3) management of neonates with gastroschisis on the neonatal intensive care unit if available.
Primary Outcome Measure Information:
Title
All-cause, in-hospital mortality
Description
Percentage of patients with gastroschisis dying in hospital during their primary admission.
Time Frame
Mortality whilst in hospital during primary admission, up to 30-days post-intervention or 30-days from admission for those not receiving an intervention and still in hospital.
Secondary Outcome Measure Information:
Title
Percentage of patients experiencing a major complication within 30-days of primary intervention*
Description
Major complications are secondary bowel ischaemia, necrosis or perforation requiring resection**, abdominal compartment syndrome*** or need for further unplanned surgical intervention. *Defined as the first bowel intervention the neonate received including silo application or primary closure. **Defined as bowel necrosis or perforation that was not present prior to primary intervention and hence occurred after primary intervention. ***Defined as respiratory insufficiency secondary to compromised tidal volumes, decreased urine output by falling renal perfusion (<1ml/kg/hr) and any other organ dysfunction caused by increased intra-abdominal pressure (based on clinical judgement - the pressure does not have to be measured to fulfil the criteria).
Time Frame
Within 30-days of primary intervention.
Title
Length of hospital stay amongst survivors
Description
In days.
Time Frame
Up to a maximum of 30-days following primary intervention.
Title
Time to full enteral feeds
Description
In days
Time Frame
Up to a maximum of 30-days following primary intervention.
Title
Need for ventilation
Description
Yes/ no. This does not include ventilation given during anaesthesia for intervention(s).
Time Frame
Up to a maximum of 30-days following primary intervention.
Title
Duration of ventilation
Description
IN days. All ventilation types included.
Time Frame
Up to a maximum of 30-days following primary intervention.
Other Pre-specified Outcome Measures:
Title
Service delivery outcomes: time from birth to arrival at the study centre
Time Frame
Time from birth to arrival at the study centre (typically less than 1 week)
Title
Service delivery outcomes: proportion of patients with clear plastic bowel coverage prior to arrival to the study centre
Time Frame
Birth to arrival at the study centre (typically less than 1 week)
Title
Service delivery outcomes: proportion of patients with intravenous fluids prior to arrival at hospital.
Time Frame
Birth to arrival at the study centre (typically less than 1 week)
Title
Service delivery outcomes: time from arrival to primary intervention
Time Frame
In-hospital, up to a maximum of 30-days from presentation to the study centre.
Title
Service delivery outcomes: position of multi-disciplinary team members involved during the initial resuscitation, primary intervention and defect closure
Description
Both in person and involved via telephone and other communication.
Time Frame
In hospital, within 30-days of presentation to the study centre
Title
Service delivery outcomes: proportion of patients receiving parenteral nutrition at some point during their hospital study
Time Frame
Up to a maximum of 30-days following primary intervention.
Title
Implementation outcome: acceptibility [assessed using the validated 'Acceptability of Intervention Measure' (AIM) Survey]
Description
Acceptability: Perception amongst stakeholders that the new intervention is agreeable. The AIM Survey has 4 questions scored from 1 (completely disagree) to 5 (completely agree). The maximum score is 20 indicating the highest level of acceptability. The lowest score is 4 indicating that the intervention is completely unacceptable.
Time Frame
Survey to be administered at 2 time points: 1) during the 4th week of the implementation phase of the study (1 week) 2) on completion of the study (4 weeks).
Title
Implementation outcome: adoption
Description
Adoption: Intention to apply new intervention. This will be assessed using the validated NoMAD Survey. The NoMAD Survey has questions categorised into 4 themes regarding the intervention: 1) understanding/ opinion, 2) participation, 3) action, 4) monitoring. Each question is scored from 1 (strongly disagree) to 5 (strongly agree). There are 20 questions in total with a maximum score of 100. There are an additional 3 questions regarding the staff members familiarity and use of the intervention scored from 0-10, with 30 being the highest score. Hence, the highest overall score is 130 and lowest 20.
Time Frame
Survey to be administered at 2 time points: 1) during the 1st week of the implementation phase of the study (1 week) 2) on completion of the study (4 weeks).
Title
Implementation outcome: appropriateness [assessed using the validated 'Intervention Appropriateness Measure' (IAM) Survey].
Description
Appropriateness: Perceived relevance of the intervention for the setting and problem.The IAM Survey has 4 questions scored from 1 (completely disagree) to 5 (completely agree). The maximum score is 20 indicating the highest level of intervention appropriateness for the setting. The lowest score is 4 indicating that the intervention is completely inappropriate.
Time Frame
Survey to be administered at 2 time points: 1) during the 4th week of the implementation phase of the study (1 week) 2) on completion of the study (4 weeks).
Title
Implementation outcome: feasibility [assessed using the validated 'Feasibility of Intervention Measure' (FIM) Survey].
Description
Feasibility: Extent to which an intervention can be applied. The FIM Survey has 4 questions scored from 1 (completely disagree) to 5 (completely agree). The maximum score is 20 indicating the highest level of feasibility. The lowest score is 4 indicating that the intervention is completely unfeasible for the setting.
Time Frame
Survey to be administered at 2 time points: 1) during the 4th week of the implementation phase of the study (1 week) 2) on completion of the study (4 weeks).
Title
Implementation outcome: fidelity.
Description
The proportion of management protocol components completed as intended will be assessed using a checklist at the time of preformed silo application and defect closure.
Time Frame
18-months (post-implementation phase of the study).
Title
Implementation outcome: fidelity.
Description
Number of centres where the study leads inputted into the study design and protocol.
Time Frame
1 year (pre-intervention phase)
Title
Implementation outcome: fidelity.
Description
Total number and position of the MDT members engaged in the qualitative study and/ or Delphi process.
Time Frame
6 months (pre-intervention phase)
Title
Implementation outcome: fidelity.
Description
Did an in-person co-development meeting take place at the start of the implementation phase at each study site (yes/ no).
Time Frame
9 months (during the implementation phase of the study)
Title
Implementation outcome: fidelity.
Description
If an in-person co-development meeting took place at the start of the implementation phase at each study site were adaptations made to the interventional bundle accordingly (yes/no).
Time Frame
9 months (during the implementation phase of the study)
Title
Implementation outcome: fidelity.
Description
If an in-person co-development meeting took place at the start of the implementation phase at each study site, the total number and position of MDT members present during the meeting.
Time Frame
9 months (during the implementation phase of the study)
Title
Implementation outcome: fidelity.
Description
Total number and position of the MDT members completing the 1-day gastroschisis training day.
Time Frame
9 months (during the implementation phase of the study)
Title
Implementation outcome: fidelity.
Description
Proportion of referral hospitals receiving implementation of the pre-hospital management protocol through in-person education and training.
Time Frame
9 months (during the implementation phase of the study)
Title
Implementation outcome: coverage
Description
The proportion of eligible patients who actually receive the intervention will be determined through the data entered into REDCap on all patients presenting with gastroschisis. Neonates with simple gastroschisis included within the study will have all data points completed. Neonates with complex gastroschisis excluded from the study intervention will have baseline data collected on the following: patient demographics, pre-hospital care and outcomes.
Time Frame
18-months (during the post-implementation phase of the study).
Title
Implementation outcome: cost
Description
The average cost per patient with gastroschisis will be estimated at each of the study centres, pre- and post-intervention. The implementation costs will also be calculated. The number of disability-adjusted life years (DALYs) averted through implementation of the interventional bundle will be calculated. The previously utilised disability-weight of 0.2 will be used for surviving neonates with gastroschisis where 0 is no disability and 1 is death 2. The cost in US$ per DALY averted will be calculated.
Time Frame
During the 2-years of data collection including pre- and post-implementation phases of the study.
Title
Implementation outcome: sustainability [assessed using the NHS Quality Improvement Sustainability Model]
Description
This model quantitatively evaluates process, staff and organisation providing a score for the overall likelihood of sustainability for a newly implemented intervention. The maximum score is 100, with a score of over 55 deemed 'reason for optimism'.
Time Frame
At 3 specific time points in the study: 1) At the time of protocol development (3 months), 2) just prior to implementation of the interventional care bundle (1 week), 3) upon completion of the study (1 week).

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: all neonates presenting primarily to the study centre with simple gastroschisis regardless of weight, gestational age or co-morbidities. Exclusion Criteria: all neonates with 'complex gastroschisis' requiring surgical intervention for bowel necrosis, perforation, atresia or other reason.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Naomi J Wright, MBChB BSc MRCS DCH MSc
Phone
0044 7824468954
Email
paedsurg.research@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Naomi J Wright, MBChB BSc MRCS DCH MSc
Organizational Affiliation
King's College London
Official's Role
Principal Investigator
Facility Information:
Facility Name
McGill University
City
Montréal
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dan Poenaru
Email
dpoenaru@gmail.com
First Name & Middle Initial & Last Name & Degree
Dan Poenaru
Facility Name
Korle-Bu Teaching Hospital
City
Accra
Country
Ghana
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
William Appeadu-Mensah
Email
wappmens@gmail.com
First Name & Middle Initial & Last Name & Degree
Afua Hesse
Email
afuahesse@gmail.com
First Name & Middle Initial & Last Name & Degree
William Appeadu-Mensah
First Name & Middle Initial & Last Name & Degree
Afua Hesse
First Name & Middle Initial & Last Name & Degree
Hope Glover-Addy
First Name & Middle Initial & Last Name & Degree
Victor Etwire
First Name & Middle Initial & Last Name & Degree
Samuel Osei-Nketiah
First Name & Middle Initial & Last Name & Degree
Awo Smart-Yeboah
First Name & Middle Initial & Last Name & Degree
Clement Agyekum Nyame
First Name & Middle Initial & Last Name & Degree
Cherno Jallow
First Name & Middle Initial & Last Name & Degree
Lawrence Kankpenyeng
Facility Name
Komfo Anokye Teaching Hospital
City
Kumasi
Country
Ghana
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Amoah
Email
daddylumba@hotmail.com
First Name & Middle Initial & Last Name & Degree
Boateng Nimako
Email
bnimako@yahoo.com
First Name & Middle Initial & Last Name & Degree
Micheal Amoah
First Name & Middle Initial & Last Name & Degree
Boateng Nimako
First Name & Middle Initial & Last Name & Degree
Abiboye Yifieyeh
First Name & Middle Initial & Last Name & Degree
Dr Plange-Rhule
First Name & Middle Initial & Last Name & Degree
John Adaebi
First Name & Middle Initial & Last Name & Degree
Fareeda Agyei
First Name & Middle Initial & Last Name & Degree
Robert Sagoe
Facility Name
Tamale Teaching Hospital
City
Tamale
Country
Ghana
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephen Tabiri
Email
kstephenba@yahoo.com
First Name & Middle Initial & Last Name & Degree
Francis Abantanga
Email
frankabantanga@hotmail.com
First Name & Middle Initial & Last Name & Degree
Stephen Tabiri
First Name & Middle Initial & Last Name & Degree
Francis Abantanga
First Name & Middle Initial & Last Name & Degree
Alhassan Abdul-Mumin
First Name & Middle Initial & Last Name & Degree
Teddy Theophilus Kojo Anyomih
First Name & Middle Initial & Last Name & Degree
Sheila Owusu
First Name & Middle Initial & Last Name & Degree
Anthony Davor
First Name & Middle Initial & Last Name & Degree
Dominic Bagbio
First Name & Middle Initial & Last Name & Degree
German Azahares Leal
Facility Name
Kamuzu Central Hospital
City
Lilongwe
Country
Malawi
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bip Nandi
Email
bipnandi@hotmail.com
First Name & Middle Initial & Last Name & Degree
Omar Jagot
Email
omarmagnum@gmail.com
First Name & Middle Initial & Last Name & Degree
Bip Nandi
First Name & Middle Initial & Last Name & Degree
Omar Jagot
First Name & Middle Initial & Last Name & Degree
Kennedy Kachingwe
First Name & Middle Initial & Last Name & Degree
Blessings Chiluza
First Name & Middle Initial & Last Name & Degree
Ulemu Chikhadzula
Facility Name
Muhimbili National Hospital
City
Dar Es Salaam
Country
Tanzania
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zaitun Bokhary
Email
zaitunsanya2005@gmail.com
First Name & Middle Initial & Last Name & Degree
Godfrey Sama
Email
godfreysama2@yahoo.com
First Name & Middle Initial & Last Name & Degree
Zaitun Bokhary
First Name & Middle Initial & Last Name & Degree
Godfrey Sama
First Name & Middle Initial & Last Name & Degree
Yona Ringo
First Name & Middle Initial & Last Name & Degree
Robert Bahati
First Name & Middle Initial & Last Name & Degree
Dr Marycharles
First Name & Middle Initial & Last Name & Degree
Dr Majaliwa
First Name & Middle Initial & Last Name & Degree
Martha Mkony
Facility Name
King's Centre for Global Health and Health Partnerships, King's College London
City
London
ZIP/Postal Code
SE5 9RJ
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Naomi J Wright, MBChB BSc MRCS DCH MSc
Phone
0044 7824468954
Email
paedsurg.research@gmail.com
First Name & Middle Initial & Last Name & Degree
Andrew Leather, MS FRCS FRCS(Ed)
Phone
0044 20 7848 5806
Email
andy.leather@kcl.ac.uk
First Name & Middle Initial & Last Name & Degree
Naomi J Wright, MBChB BSc MRCS DCH MSc
First Name & Middle Initial & Last Name & Degree
Andy Leather
First Name & Middle Initial & Last Name & Degree
Nick Sevdalis
First Name & Middle Initial & Last Name & Degree
Niyi Ade-Ajayi
First Name & Middle Initial & Last Name & Degree
Justine Davies
Facility Name
University Teaching Hospital
City
Lusaka
Country
Zambia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bruce Bvulani
Email
bvulanib@yahoo.com
First Name & Middle Initial & Last Name & Degree
Rae Oranmore Brown
Email
raeobrown@icloud.com
First Name & Middle Initial & Last Name & Degree
Lupando Mukonge
First Name & Middle Initial & Last Name & Degree
Bruce Bvulani
First Name & Middle Initial & Last Name & Degree
Rae Oranmore-Brown
First Name & Middle Initial & Last Name & Degree
Patricia Shinondo
Facility Name
Arthur Davison Children's Hospital
City
Ndola
Country
Zambia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sam Miti
Email
drsammiti@gmail.com
First Name & Middle Initial & Last Name & Degree
Mwewa Mwape
Email
mwapemwewa2000@yahoo.com
First Name & Middle Initial & Last Name & Degree
Sam Miti
First Name & Middle Initial & Last Name & Degree
Mwewa Mwape
First Name & Middle Initial & Last Name & Degree
Mwambazi Chiwali
First Name & Middle Initial & Last Name & Degree
Jonathon Kaunde Mwansa

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Following publication, the full anonymised dataset will be made opening available to the public.
Citations:
PubMed Identifier
30984879
Citation
Wright N, Abantanga F, Amoah M, Appeadu-Mensah W, Bokhary Z, Bvulani B, Davies J, Miti S, Nandi B, Nimako B, Poenaru D, Tabiri S, Yifieyeh A, Ade-Ajayi N, Sevdalis N, Leather A. Developing and implementing an interventional bundle to reduce mortality from gastroschisis in low-resource settings. Wellcome Open Res. 2019 Mar 8;4:46. doi: 10.12688/wellcomeopenres.15113.1. eCollection 2019.
Results Reference
derived

Learn more about this trial

Multi-Centre Gastroschisis Interventional Study Across Sub-Saharan Africa

We'll reach out to this number within 24 hrs